---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-071350"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:19:34.287620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio reports Q4 2022 net loss $20.8M, cash $661M; advances NUV-868 and DDC

## Summary
- Net loss Q4 2022 $20.8M ($0.10/sh) vs $25.1M ($0.12/sh) Q4 2021; full-year net loss $104.2M.
- Cash, equivalents and marketable securities $661.0M as of Dec 31, 2022; no debt disclosed.
- R&D expense Q4 2022 $16.9M (down from $22.0M); G&A $7.4M (vs $7.6M) YoY.
- Dosed first patient in Phase 1b combo study of NUV-868 with olaparib or enzalutamide; Phase 1 monotherapy ongoing.
- Nominated first DDC clinical candidate; expects IND submission by end of 2023.

## SEC filing metadata
- accession: 0001193125-23-071350
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/0001193125-23-071350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/d481540d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-071350
- JSON: https://secwatch.observer/filing/0001193125-23-071350.json
- Plain text: https://secwatch.observer/filing/0001193125-23-071350.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income a net loss of $20.8 million, or $(0.10) per share, EPS $(0.10) per share.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Net income: a net loss of $20.8 million, or $(0.10) per share
  - EPS: $(0.10) per share
  - Result: reported results
  source text: On March 15, 2023, Nuvation Bio Inc. issued a press release announcing its financial results for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312523071350/0001193125-23-071350-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.